PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 24: Articles 11501-12000 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. The influence of steroidal contraceptives and lactation on bone loss emerging as a major research issue.
  2. Influence of triphasic oral contraceptives on blood rheology and hemostatic and metabolic patterns in young women: results of a three-year study.
  3. Information, education and communication strategy for family planning. [Strategie d'information, education et communication en planification familiale.]
  4. Information, education, communication and motivation (IECM): strategy and master plan for the Philippine Family Planning Programme (PFPP), 1992-1994.
  5. Injectable and implantable contraceptives.
  6. Injectable contraception: the USA perspective.
  7. Injectable contraceptives. Report of the Seminar on Injectable Contraceptives, January 27, 1992. [Anticonceptivos inyectables. Informe del Seminario sobre Anticonceptivos Inyectables, 27 de Enero de 1992.]
  8. Injectable contraceptives: safe, effective but neglected. Questions and answers.
  9. Innovations in contraception: the Norplant system.
  10. INOPAL II final technical report: Self-Financed Incorporation of Family Planning in Rural Fincas in Guatemala, Contract Number CI90.58A, June 1, 1990 to March 31, 1992. Prepared by: El Patronato para el Mejoramiento de la Salud de los Trabajadores Agricola (AGROSALUD) and the Population Council.
  11. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
  12. The Integrated Project: a humane approach to family planning. [Le Project integre: une approche humaine de la P.F.]
  13. The integration of family planning programs into rural development programs. [L'integration des programmes de planning familial dans les programmes de developpement rural.]
  14. Interaction between clients and grass-root family planning workers in Korea: implications for program performance.
  15. Interaction between clients and grass-root family planning workers: implications for programme performance.
  16. Interchangeability of oral contraceptive products [letter]
  17. International family planning and Pro Familia: comments of a committed member. [Internationale Familienplanung und Pro Familia: Anmerkungen eines engagierten Mitglieds.]
  18. International oral contraceptive working group issues consensus statement on compliance. News release.
  19. International Planned Parenthood Federation medical and service delivery guidelines for family planning.
  20. Intrauterine contraception.
  21. The intrauterine contraceptive device (IUD) (letter) [Az intrauterin fogamzasgatlo eszkoz.]
  22. Introduction: Enhancing oral contraceptive compliance and efficacy.
  23. IPPF and family planning in the GDR. [IPPF und Familienplanung in der DDR.]
  24. IPPF family planning congress.
  25. Iran: the family-planning challenge.
  26. Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment.
  27. Is family planning failing?
  28. Is hormonal contraception a time bomb? [Onko hormonilaakitys tuntematon aikapommi.]
  29. Is lactation nature's contraceptive? Data from Samoa.
  30. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study.
  31. Is users' knowledge about contraceptives adequate? A case study of Finnish IUD users.
  32. Islamic ideology, contraception and the emergence of women in Bangladesh.
  33. It all started from worms: the 45-year record of Japan's post-World War II national health and family planning movement.
  34. IUD guidelines for family planning service programs: a problem solving reference manual.
  35. IUD insertion or a prescription for oral contraceptives immediately after an induced abortion. [Inzerce IUD anebo preskripce oralni kontracepce bezprostredne po provedeni miniinterrupce.]
  36. Kenya Assessment Program for Permanent and Long-Term Contraception, 31 August to 16 September 1992.
  37. Knowledge, attitudes and practice of family planning at Mgeta Morogoro Rural -- a baseline survey done prior to the introduction of the integrated family planning, nutrition and parasite control project (IP)
  38. Labour and population. Women's work and family welfare: informal women's groups and family planning information and services.
  39. The lactational amenorrhea method: a new hormonal family planning method.
  40. Ladycomp as an aid in natural family planning.
  41. The Lagana' model of contraceptive health behavior: an experimental test of its effectiveness.
  42. LAM acceptability among family planning clients: process analysis and interim results of a pilot study. Draft.
  43. Late adolescent sexuality and contraception: the influence of sex role orientation, locus-of-control, illusion of fertility control, and experience.
  44. The law and planned parenthood case report.
  45. Learning contraception. Improved reproductive health through a three hour guide to contraceptive options as the 20th century draws to a close.
  46. Legal aspects of teenage girls' reproductive health in Tanzania: a look at contraception, abortion and infanticide.
  47. Let's talk about Norplant: advances in steroidal contraception. [Hablemos del Norplant: avances en anticoncepcion esteroidea.]
  48. The level of participation in a family planning survey using personal interviews. [Grado de participacion en una encuesta sobre planificacion Familiar mediante entrevista personal.]
  49. LHRH analogues for contraception in women.
  50. Men targeted for family planning in Zambia.
  51. Men, neomachismo and family planning. [Varones, neomachismo y planeacion familiar.]
  52. The metabolic impact of oral contraceptives.
  53. Midterm evaluation of Contraceptive Development and Research in Immunology Project (CD&RI) (USAID/India Project 386-0500)
  54. Midterm evaluation of the Association for Voluntary Surgical Contraception (AVSC) Cooperative Agreement.
  55. Mixed results mark Asian family planning. China and India must increase the reach of their family-planning programs, reports say.
  56. Mixed results mark Asian family planning. Indonesia bids to transfer successful program in family planning to other developing nations.
  57. The more resources will be needed, Chairman of the National Family Planning Coordinating Board (BKKBN) of Indonesia Haryono Suyono says, "as the program becomes more successful."
  58. Motherhood by choice: pioneers in women's health and family planning.
  59. Mrs. Rahima's village: a new look at family planning in Kalishpur. Case scenarios for training and group discussion.
  60. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol.
  61. Multivariate model of adolescent sexual activity and contraceptive use in Lima and Mexico City.
  62. Mum's the word: the Supreme Court and family planning.
  63. The mystique of first intercourse among college youth: the role of partners, contraceptive practices, and psychological reactions.
  64. National family planning service guidelines. Contraception.
  65. National Family Planning v. Sullivan [3 November 1992]
  66. Natural family planning in developing countries [letter]
  67. Natural family planning.
  68. Natural family planning. [Naturlig familjeplanering (NFP)]
  69. Natural methods of contraception.
  70. Natural methods of contraception. [Les methodes naturelles de contraception.]
  71. The needs of women versus the interests of family planning personnel, policy-makers and researchers: conflicting views on safety and acceptability of contraceptives.
  72. Negotiating birth control in village China.
  73. New concepts in contraception: Norplant subdermal implant.
  74. New concepts in oral contraceptive pill use.
  75. New contraceptive implant receives wide acclaim in Nigeria.
  76. New contraceptive method, female-worn condom, approved by FDA panel.
  77. New contraceptive technologies.
  78. New contraceptive vaccines, implants may prove promising.
  79. New developments in contraceptive technology.
  80. The new era in oral contraception: pills containing gestodene, norgestimate, and desogestrel.
  81. The new Europe: recent developments and their impact on family planning.
  82. New nonhormonal contraceptive methods for men.
  83. New oral contraceptive progestogens.
  84. New oral contraceptives improve patient compliance. News release.
  85. The new pills: awaiting the next generation of oral contraceptives.
  86. The "new" contraceptive method of breastfeeding.
  87. The newest contraceptive: the Norplant system.
  88. The newly-weds' decisions on contraception.
  89. Nigerbus family planning monitor, February 1992.
  90. Nigeria: the Family Planning Situation Analysis Study. Final report (condensed)
  91. Non-oral hormonal contraceptives: injectables, implants and vaginal rings.
  92. Nonclinical approaches to family planning service provision: the Zairian experience. [Approches non cliniques de prestation des services de planification familiale: l'experience Zairoise.]
  93. Noncontraceptive benefits of modern low-dose oral contraceptives.
  94. Noncontraceptive benefits of oral contraceptives.
  95. Norplant -- welcome new contraceptive option.
  96. Norplant adoption: comparison of early Norplant adopters and oral contraceptive users in a family planning clinic in Baltimore.
  97. The Norplant contraceptive [letter]
  98. The Norplant contraceptive [letter]
  99. The Norplant contraceptive. [Author's reply] [letter]
  100. Norplant guidelines for family planning service programs.
  101. Notes and reflections on interviews with family planning service providers. Options II project. Family Planning Regulatory Activity in Senegal.
  102. Nurse practitioners and insertion of the Norplant contraceptive device.
  103. Nutrition and family planning linkages: what more can be done?
  104. Nutrition and population links: breastfeeding, family planning and child health. Papers from the ACC / SCN 18th Session Symposium.
  105. Observations with a tri-phasic oral contraceptive (Tri-Regol) in everyday clinical practice.
  106. Obstetric and contraceptive surgery at the district hospital: a practical guide.
  107. Operations research in family planning: report on a national training workshop, Bangalore, May 20-30, 1992.
  108. Operations research project on the improvement of family planning services of the Ministry of Health in Iquitos. Progress report. [Proyecto de investigacion operativa para el mejoramiento de los servicios de planifaction familiar del Ministerio de Salud en Iquitos. Informe de avance.]
  109. Options for immunocontraception and issues to be addressed in the development of birth control vaccines.
  110. Oral contraception affects osteocalcin serum profiles in young women.
  111. Oral contraception noncompliance: the extent of the problem.
  112. Oral contraception: where do we stand?
  113. Oral contraceptive "potencies" and deep venous thromboembolism [letter]
  114. Oral contraceptive marketing in Ibadan, Nigeria.
  115. Oral contraceptive use and breast cancer: a case-control study in Ujungpandang, South Sulawesi, Indonesia, 1990-1991.
  116. Oral contraceptive use and cardiovascular disease: is the relationship real or due to study bias?
  117. Oral contraceptive use and cervical intraepithelial neoplasia.
  118. Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results.
  119. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women.
  120. Oral contraceptive use and the risk of Type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women.
  121. Oral contraceptive user guide. 2nd ed.
  122. Oral contraceptives and breast cancer [letter]
  123. Oral contraceptives and breast cancer risk in Denmark.
  124. Oral contraceptives and breast cancer. A review with some comments on mathematical models.
  125. Oral contraceptives and breast cancer. Reply of the authors [letter]
  126. Oral contraceptives and breast cancer: any relationship?
  127. Oral contraceptives and cancer of the cervix uteri. A meta-analysis.
  128. Oral contraceptives and drug interactions. Patient guide.
  129. Oral contraceptives and gynecologic cancer: an update for the 1990s.
  130. Oral contraceptives and human papillomavirus infection in cervical intraepithelial neoplasia.
  131. Oral contraceptives and neoplasia: report of a WHO scientific group.
  132. Oral contraceptives and non-contraceptive oestrogens in the risk of gallstone disease requiring surgery.
  133. Oral contraceptives and panic disorder.
  134. Oral contraceptives and pregnancy in relation to peptic ulcer.
  135. Oral contraceptives and primary liver cancer among young women.
  136. Oral contraceptives and risk of benign proliferative epithelial disorders of the breast.
  137. Oral contraceptives and venous thromboses in adolescents undergoing elective surgery: a case report, and review of the literature.
  138. Oral contraceptives caused thrombosis in a monoovular twin with protein C deficiency, while the other, without medication, remained asymptomatic [letter]
  139. Oral contraceptives in ancient and medieval times.
  140. Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations.
  141. Oral contraceptives still misunderstood [letter]
  142. Oral contraceptives.
  143. Order No. 032/MDS/P/PF/MSP of 30 July 1992 defining the rules and standards for maternal-child health and family planning services. [Arrete no. 032/MDS/P/PF/MSP du 30 juillet 1992, portant definition des normes et standards des services de sante maternelle et infantile et de planification familiale.]
  144. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise.
  145. An ounce of prevention. Is family planning disappearing from the healthcare picture?
  146. Our obligation is to define the liberty of all. Excerpts from the opinion for the Supreme Court in Planned Parenthood of Southeastern Pennsylvania v. Casey.
  147. Ovarian suppressive activity of a low dose monophasic oral contraceptive during correct and incorrect pill intake. [Etude de l'activite contraceptive d'une pilule minidosee lors de son utilisation correcte ou incorrecte.]
  148. Pakistan's fertility and family planning: future directions.
  149. Pamphlets about injectable contraceptives.
  150. Participation in family planning in Tanzania. The UMATI programme.
  151. Partner-specific condom use among adolescent women clients of a family planning clinic.
  152. Passive immunization against prostatic "inhibin" peptide as a male contraceptive.
  153. The peculiarities of hormonal contraception in hyperandrogenic women.
  154. Pelvic pain and pelvic joint instability, association with oral contraceptives. Reply [letter]
  155. The performance of non-governmental organizations in family planning and MCH in Maharashtra State.
  156. Personal values and contraceptive choices.
  157. Perspectives on sexuality, contraception, and pregnancy among black teenaged women.
  158. Pharmacist's contraceptive training manual. Ghana Social Marketing Programme (GSMP)
  159. Pharmacokinetics and protein binding of gestodene under treatment with a low-dose combination oral contraceptive for three months.
  160. Pharmacokinetics and serum protein binding of 3-keto-desogestrel in women during three cycles of treatment with a low-dose combination oral contraceptive.
  161. Pharmacokinetics and serum protein binding of gestodene and 3-keto-desogestrel in women after single oral administration of two different contraceptive formulations.
  162. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
  163. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
  164. Planned Parenthood Association of Ghana (PPAG), 1967-1992.
  165. The Planned Parenthood Federation of Nigeria experience.
  166. Planned Parenthood v. Casey [29 June 1992]
  167. Planned Parenthood v. Neely [14 September 1992]
  168. Planning your family safely.
  169. Plasma fibrinogen: its relationship with oral contraception, the menopause, and hormone replacement therapy.
  170. Plasma prolactin in relation to menstrual cycle phase, oral contraceptive use, arousal time and smoking habits.
  171. Plasminogen levels in healthy volunteers -- influence of age, sex, smoking and oral contraceptives.
  172. Policy approaches to the removal of medical barriers: improving quality of care and increasing access to family planning services.
  173. Policy implication of family planning integration with maternal and child health program of Korea.
  174. Popularizing spacing methods of family planning in rural areas: the perception of programme personnel and the community in Karnataka.
  175. Population / family planning program communication strategies, Philippine experience.
  176. Population and family planning programs in Byumba. [Les programmes de population et planification familiale a Byumba.]
  177. Population and family planning research in Bangladesh: an annotated bibliography. Fifth volume.
  178. Population and family planning statistics of China, 1988-1991.
  179. The Population Council INOPAL II Program final report. The institutionalization of postpartum family planning in Peru. PROFAMILIA, Promocion de Labores Educativas y Asistenciales en Favor de la Salud; IPSS, Instituto Peruano de Seguridad Social. Contract Number CI90.84A, July 1, 1990 - December 31, 1992.
  180. The population factor: China's family planning policy in the 1990s.
  181. Population policy and family planning issues in China. [A nepessegpolitika es a csaladtervezes kerdesei kinaban.]
  182. Possible interaction between oxcarbazepine and an oral contraceptive.
  183. Post-coital contraceptive agents from extracts of Sri Lankan alcyonacean soft corals -- I.
  184. Post-partum contraceptive preference in high-risk parturients in Maputo.
  185. Postcoital contraception underrecognized and underutilized.
  186. Postcoital contraception.
  187. Postpartum contraception in Mexico City's hospitals. [La practica de anticoncepcion posparto en hospitales del Distrito Federal.]
  188. Postpartum contraception: perspectives from clients and service providers in Kenya.
  189. Postpartum contraception: perspectives from clients and service providers in six countries. Final report.
  190. The power of mass media rediscovered: the family planning communication campaign of Turkey.
  191. Practical experience in the UK with an oestrogen / progestogen contraceptive vaginal ring.
  192. Predictors of adolescent female decision making regarding contraceptive usage.
  193. Premarital sexual activity and contraceptive use in Santiago, Chile.
  194. Premature discontinuation of contraception in Australia.
  195. Prescribing contraceptives -- a challenge for nursing.
  196. The present and future of family planning in Turkey.
  197. Preserving the gains of the past: training for surgical contraception in Bangladesh.
  198. President Soeharto and family planning.
  199. Previous use of intrauterine devices and oral contraceptives and spontaneous abortion of known karyotype.
  200. Private sector approaches to effective family planning.
  201. The private sector in family planning: its role and financing.
  202. Problem-solving appraisal, oral contraceptive use, and menstrual pain.
  203. Proceedings of the Twenty-Fourth Annual Conference, Association for Population/Family Planning Libraries and Information Centers--International: accessing public information.
  204. A process for service quality improvement in family planning.
  205. A process for service quality improvement in family planning. Draft.
  206. Procoagulant changes induced by oral contraceptives are balanced by an increased fibrinolytic tendency.
  207. Profile of oral contraceptive usage by females of the northern part of West Bengal.
  208. A profile of young adolescents attending a teen family planning clinic.
  209. Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings.
  210. Progesterone-releasing vaginal rings for use in postpartum contraception. II. Pharmacokinetic profiles in women.
  211. The progestin-only oral contraceptive -- its place in postpartum contraception.
  212. Progestogen only contraceptives and ectopic pregnancy.
  213. Progress with contraceptives and abortifacients.

     

  214. Project for Promotion of Population Education. Report on the KAP survey of family planning and media environment.
  215. Project for Promotion of Population Education. Report on the needs survey of family planning activities of midwives.
  216. Promoting family planning in Romania. Phase one of qualitative research with detailed group interviews, Bucharest, February 1992. [Promouvoir la planification familiale en Roumanie. Premiere phase de recherche qualitative, entretiens de groupes approfondis, Bucarest, Fevrier 1992.]
  217. Promoting family planning in Rumania. Qualitative research, February - July 1992.
  218. Promoting family planning in Rumania. Third phase of qualitative research. Focus group discussions, Tirgu-Mures, July 1992.
  219. Promoting family planning: findings from operations research and program research.
  220. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive.
  221. A prospective, one-year study on the effects of two long acting injectable contraceptives (depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids.
  222. Protein C deficiency as the cause of a deep venous thrombosis in a patient under treatment with oral contraceptives (letter) [Deficit de proteina C como causa de trombosis venosa profunda en una paciente en tratamiento con anticonceptivos orales.]
  223. Protracted cholestasis probably induced by oral contraceptive.
  224. Provider knowledge concerning Depo-Provera and other contraceptives before and after training: a study in rural Peru.
  225. Providing contraceptives through community based services with clinical back-up: a model protocol for quality of care.
  226. Proximity to contraceptive services and fertility transition in rural Kenya.
  227. Public funding for U.S. contraceptive services down since 1980 -- $95 million a year goes to sterilization.
  228. Pulmonary embolus in an adolescent on oral contraceptives.
  229. Qualitative study of male attitudes to family planning, Pakistan. In-depth interviews, July, 1992.
  230. A quality assurance manual. Essential clinical standards for contraceptive service delivery for IPPF family planning associations in East and South East Asia.
  231. Quality issues in family planning.
  232. Quality of care in family planning service delivery. A survey of cooperating agencies of the Family Planning Services Division, Office of Population, U.S. Agency for International Development.
  233. Quality of care in family planning: clients' rights and providers' needs.
  234. Quality of family planning counseling for community-based distribution agents and clinic providers in Kenya.
  235. Quality of family welfare services in increasing the acceptance and continuation of contraception: the case of India.
  236. Quality of health and family planning services in rural Uttar Pardesh: the client's view.
  237. A question of control. Women's perspectives on the development and use of contraceptive technologies. Report of an international conference held in Woudschoten, the Netherlands, April 1991.
  238. Race, integration and family planning in Trinidad and Tobago.
  239. A randomized, double-blind, placebo-controlled comparison of the impact of low-dose and triphasic oral contraceptives on follicular development.
  240. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
  241. Recent advances in contraception and family planning. [Avances recientes en anticoncepcion y planificacion familiar.]
  242. Recent changes in the national family planning program and its future directions in the ROC.
  243. A recipe for success: ingredients for a successful family planning program.
  244. Reducing Medical Barriers and Improving Contraceptive Image, June 18, 1992, Washington, D.C.. Summary report.
  245. Reflections on appropriate approaches to the provision of family planning services. [Reflexions autour des approches appropriees en matiere de prestations de services de planification familiale.]
  246. Regulations and procedures that undermine service delivery and encourage high fertility: observations and suggested activities. Options II project. Family Planning Regulatory Activity in Senegal.
  247. The relationship between contraceptives, sexual practices, and cervical human papillomavirus infection among a college population.
  248. The relationship between local family planning expenditures and fertility in Thailand, 1976-1981.
  249. The relevance of migraine to contraceptive use.
  250. Removal of retained intrauterine contraceptive devices in pregnancy.
  251. Report of the Pre-Conference Seminar on Planning and Implementation of Effective Family Planning / Family Health and Welfare Programmes: Some Lessons from the Asian and Pacific Region, 17-21 March 1992, Beijing.
  252. Report on a family planning activity.
  253. Report on Pakistan Workshop on Introduction to Operations Research in Family Planning, January 20-22, 1992, Lahore, Pakistan. Final report.
  254. Report on the needs survey of family planning activities of midwives.
  255. Reproductive knowledge, and contraceptive awareness and practice among secondary school pupils in Bagamoyo and Dar-es-Salaam, Tanzania.
  256. Requirements or incentives by government for the use of long-acting contraceptives.
  257. Residual sperm function in oligozoospermia induced by testosterone enanthate administered as a potential steroid male contraceptive.
  258. Restructuring federalism: the effects of decentralized federal policy on states' responsiveness to family planning needs.
  259. Reversible contraception for the woman over 35 years of age.
  260. A review of recent findings on family planning service delivery quality and the roles of men in family planning in Zimbabwe, 1990 - 1992.
  261. A review of the effects of long-acting progestogen-only contraceptives on ovarian activity.
  262. Review of the Youth Programme of the Family Planning Association of Kenya.
  263. Review on copper in male reproduction and contraception.
  264. Risk factors for Chlamydia trachomatis infection in 6810 young women attending family planning clinics.
  265. Risk of an unintentional pregnancy after only one unprotected coitus; observations concerning today's hormonal postcoital contraceptive agents. [Het risico van een onbedoelde zwangerschap na een onbeschermde coitus; beschouwing bij de huidige hormonale postcoitale anticonceptiemethoden.]
  266. The risk of an unwanted pregnancy following one unprotected coitus; observation concerning the current hormonal postcoital contraceptive methods (letter) [Het risico van een onbedoelde zwangerschap na een onbeschermde coitus; beschouwing bij de huidige hormonale postcoitale anticonceptiemethoden.]
  267. The risk of breast cancer associated with oral contraception and hormone replacement therapy.
  268. The role of Caribbean family planning programs in AIDS prevention.
  269. The role of communication in family planning: the case of the Philippines.
  270. The role of family planning programmes as a fertility determinant.
  271. The role of family planning programs in the fertility transition in Latin America. [Los programas de planificacion familiar y su funcion en la transicion de la fecundidad en America Latina.]
  272. The role of GnRH analogues in male contraception.
  273. The role of grass-roots organizers in the development of family planning programs. Case study: Gikongoro prefecture, Rwanda. [Le role des animateurs de base dans le developpement du programme de planification familiale. Etude de cas, prefecture de Gikongoro, Rwanda.]
  274. Role of male opinion leaders in the promotion and delivery of family planning services in Cameroon.
  275. The role of the NGOs. How shall Philippine family planning be organized?
  276. Russian fertility is low, despite early age at first birth and lack of effective contraceptive methods.
  277. Safety of oral contraceptives for teenagers.
  278. The safety of oral contraceptives: epidemiologic insights from the first 30 years.
  279. Self-financed incorporation of family planning in rural fincas in Guatemala.
  280. The selling of contraception: the Dalkon Shield case, sexuality, and women's autonomy.
  281. Serum bile acids and the bile acid tolerance test under oral contraception.
  282. Serum glycocholic and glycochenodeoxycholic acids in injectable contraceptives -- noristerat and Depot provera users.
  283. Serum lipids, blood pressure, body weight, and serum chemistry in women using subcutaneous contraceptive implants releasing the progestin ST 1435.
  284. Service proximity as a determinant of contraceptive behaviour: evidence from cross-national studies of survey data.
  285. Setting contraceptive acceptor targets for small regions.
  286. Setting standards of quality in family planning programs.
  287. Sex-role orientation, self-esteem, and contraceptive use in pregnant and nonpregnant adolescent females.
  288. The sexual and contraceptive lifestyles of young people: Part I.
  289. Sexual behavior and contraceptive use among 15-24-year-olds in Uganda.
  290. Sexual behavior and use of contraception among young adults. What have we learned from the young adult reproductive health surveys in Latin America?
  291. Sexual behavior, reproductive knowledge and contraceptive use among young urban Nigerians.
  292. Sexual intercourse, contraception, and risk-taking behavior among unselected French adolescents aged 11-20 years.
  293. Sexuality, birth control and childbirth in orthodox Jewish tradition.
  294. Shy/silent contraceptive users: further evidence.
  295. Significant family planning achievements in 1991.
  296. Situation analysis of the family planning program in Burkina Faso. Final report (condensed)
  297. Situation analysis of the family planning services extension program in Ivory Coast, Association Ivoirienne pour le Bien-Etre Familial, Contract No. CI19.03A, February - October, 1992. [Analyse situationnelle du programme d'extension des services de planification familiale en Cote d'Ivoire. Association Ivoirienne pour le Bien-Etre Familial, Contrat No. CI19.03A, fevrier - octobre 1992.]
  298. A situation analysis study of the Nairobi City Commission family planning clinics. Selected findings.
  299. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
  300. Social attitudes of Filipinos towards family planning interest groups.
  301. Social change and family planning in Kenya.
  302. Socioeconomic differentials in contraceptive use and desire for more children in greater Freetown, Sierra Leone.
  303. SOMARC launches Protector condom in four more African countries to increase condom use for family planning and AIDS prevention.
  304. Songs for family planning.
  305. Sources of information, experiences and opinions on sexuality, contraception and STD protection among young Swedish students.
  306. The Soviet question: as the new commonwealth rises from the ruins, will Western family planning assistance come to the rescue?
  307. Spermicides for contraception and STD prevention: current status. [Les spermicides pour la contraception et contre les MST: le point de la situation.]
  308. SSK and family planning.
  309. Stalking the elusive "unmet need" for family planning.
  310. Standardized directions urged for taking birth control pills.
  311. Starting oral contraceptives -- which, when and how?
  312. Statement of NAACOG: the Organization for Obstetric, Gynecologic, and Neonatal Nurses on use of Depo Provera as a contraceptive.
  313. Statement on injectable contraception. Revised.
  314. Statement submitted to the FDA Advisory Committee concerning the use of depotmedroxyprogesterone acetate (Depoprovera) for contraception.
  315. Status and determinants of contraceptive knowledge among newly married couples in Shanghai municipality.
  316. Status and determinants of premarital contraceptive use in Shanghai.
  317. STDs and family planning clinics: a regional program for Chlamydia control that works.
  318. Steep decline in world fertility rates: contraceptive use up sharply.
  319. Steroid contraceptives causing no increase in risk of thromboembolism (case-control study)
  320. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment -- effect on uterine contractility.
  321. Strategic management of family planning programs.
  322. Strategies to combine AIDS and family planning in condom social marketing projects.
  323. Strategies to improve contraceptive use to influence demographic trends in African countries.
  324. Strategy for information-education-communication of population and family planning.
  325. A study of cholelithiasis during pregnancy and its relationship with age, parity, menarche, breast-feeding, dysmenorrhea, oral contraception and a maternal history of cholelithiasis.
  326. A study of contraceptive-failure pregnancy and induced abortion in Korea.
  327. Study of sustainability for the National Family Planning Board in Jamaica.
  328. Study of the periodontal conditions of hormonal contraceptive users.
  329. Study on acceptability of contraceptive methods for married fecund women in rural areas of Jiangsu province.
  330. A study on the contraceptive preference of adults aged 18-49 in Tianjin.
  331. Subcutaneous contraceptives (editorial) [Anticonceptivos por via subcutanea.]
  332. Supply and demand, not supply vs. demand: appropriate theory for the study of effects of family planning programmes on fertility.
  333. Suppression of 24-hour cholecystokinin secretion by oral contraceptives.
  334. Survey of attitudes towards the use of contraceptives in Namibia.
  335. A survey of contraceptive use and unplanned pregnancy in Perth, Western Australia.
  336. Sustainability of family planning NGOs in Bangladesh. Workshop report, August 27-28, 1991.
  337. Sustainability of family planning programmes in the 1990s.
  338. The Swiss Red Cross family planning project in Romania. [Das Familienplanungsprojekt des Schweizer Roten Kreuzes in Rumanien.]
  339. Tanzania Family Planning Communication Project: baseline family planning audience survey.
  340. Teaching family planning in the community at graduate and post-graduate levels.
  341. Techniques for improving client relations in family planning programs.
  342. Teen contraception in the 1990s.
  343. Teenage conception and contraception in the English regions.
  344. Teenagers seeking condoms at family planning services. Part II. A provider's perspective.
  345. Television and family planning.
  346. The term "egg" and contraception [letter]
  347. There's good news about birth control pills.
  348. Three intrauterine contraceptive devices in a single uterus [letter]
  349. Three year experience with Norplant contraceptive implants in Nigeria.
  350. Toward a new approach in population in Africa: the integration of family planning programs in rural development programs. [Vers une nouvelle approche d'intervention en matiere de population en Afrique: l'integration des programmes de planning familial dans les programmes de developpement rural.]
  351. Towards understanding low contraceptive prevalence in African societies.
  352. Treatment of birth control in selected women's magazines: from 1960 through 1990 from the pill through Norplant.
  353. Treatment with oral contraceptives. Swiss consensus conference on frequently discussed questions about hormonal contraception. [Behandlung mit oralen Kontrazeptiva. Schweizerische Konsensuskonferenz zu haufig diskutierten Fragen hormoneller Antikonzeption.]
  354. Trends in European family planning programs. [Tendenzen der Familienplanungsarbeit in Europa.]
  355. Trends in women's situation and family planning in South Africa.
  356. Trip report: research and evaluation technical assistance for baseline survey analysis and clinic survey data management, Tanzania Family Planning Communication Project.
  357. Twenty years of family planning in Sub-Saharan Africa. [Vingt ans de planification familiale en Afrique Sub-Saharienne.]
  358. Two aspects of family planning in Bolivia, 1989. [Dos casos de la planificacion familiar en Bolivia, 1989.]
  359. Two cases of family planning in Bolivia, 1989. I. Reproductive behavior and contraceptive practice in adolescence. II. Sterilization in the female population. [Dos casos de la planificacion familiar en Bolivia, 1989. I. Conducta reproductiva y practica anticonceptiva en la adolescencia. II. La esterilizacion en la poblacion femenina.]
  360. The U.S. and the Vatican on birth control.
  361. U.S. approves injectable drug as birth control.
  362. UK Health Secretary launches family planning initiatives.
  363. The underrated benefits of oral contraception: consequences of pregnancy and induced abortion in teenagers.
  364. UNICEF supports birth control despite Holy See.
  365. Unmet demand for contraception vs unmet demand for appropriate contraception.
  366. Unmet need for family planning in developing countries. [Ungedeckter Bedarf an Familienplanungsleistungen in Entwicklungslandern.]
  367. Update on subdermal contraceptive implants.
  368. Update on the intrauterine contraceptive device [editorial]
  369. USA: victory over gag rule for family planning groups.
  370. Use of a monophasic, low-dose oral contraceptive in relation to mental functioning.
  371. Use of and attitudes toward contraception among men and women in France (Bichat interviews, October 21, 1991. [Usages et attitudes des hommes et des femmes vis-a-vis de la contraception en France (Entretiens de Bichat -- 21 octobre 1991)]
  372. Use of birth control pills and condoms among 17-19-year-old adolescents in Norway: contraceptive versus protective behaviour?
  373. Use of clinical guidelines to enhance quality of family planning service programs in developing countries.
  374. Use of Depo Provera for contraception.
  375. Use of medical practitioners for promoting oral contraceptive pills: a feasibility study.
  376. Use of oral contraceptives by adolescents and its consequences in Finland, 1981-91.
  377. Use of the rapid evaluation method for evaluating maternal and child health and family planning services.
  378. The usefulness of operations research methodology in family planning: experience from Turkey, Bangladesh, and Pakistan.
  379. User fees for sustainable family planning services: background discussion for the Program Managers' Handbook.
  380. Utilisation of traditional healers in Bangladesh family planning programmes.
  381. Vaginal contraceptive film gains wider acceptance.
  382. Vaginal rings for contraception: endocrine parameters.
  383. Vietnam seeks help expanding voluntary surgical contraception.
  384. In Vietnam, contraceptive awareness high, use low, despite two-child policy.
  385. Vietnam: contraceptive use related to provincial infant mortality levels.
  386. What is compliance in oral contraception? News release.
  387. What's wrong with NHS family planning?
  388. When contraception fails.

     

  389. Where family planning works [editorial]
  390. Where is the planning in family planning? Fiji after three decades of family planning programmes.
  391. WHO and family planning.
  392. Woman of valor: Margaret Sanger and the birth control movement in America.
  393. Women and family planning.
  394. Women and family planning: issues for the 1990's. Discussion note.
  395. Women's development and family planning: the virtuous circle.
  396. Women's employment, education, fertility, and family planning in Vietnam: an economic perspective.
  397. Women's interests: how can family planning managers respond?
  398. Women's knowledge about contraception.
  399. Women's perspectives on contraceptive development.
  400. Women's work and family welfare: informal women's groups and family planning information and services.
  401. Women, family planning and child mortality: case study of selected areas in Kenya, Western and Coast Provinces.
  402. World access to birth control. 1992 report on world progress towards population stabilization.
  403. World population, family planning and development. [Wereldbevolking, geboortenregeling en ontwikkeling.]
  404. The worldwide contraception "boom". [El "boom" mundial de la anticoncepcion.]
  405. Worldwide variations in the lifetime probability of reproductive cancer in women: implications of best-case, worst-case, and likely-case assumptions about the effect of oral contraceptive use.
  406. Young men's contraceptive habits. [Sessionsindkaldtes praeventionsvaner.]
  407. Zaire: a situation analysis of the family planning program, comparing three service delivery systems. Final report (condensed)
  408. Zimbabwe takes action to involve males in family planning.
  409. Zimbabwe: a situation analysis of the family planning program. Final report (condensed)
  410. Zimbabwe: a situation analysis of the family planning programme.
  411. Zimbabwe: family planning via bicycle. [Zimbabwe: familie-planlegging pr. sykkel.]
  412. The Zimbabwean experience: Zimbabwe National Family Planning Council.
  413. Has family planning behavior in the Federal Republic of Germany changed since 1985? [Hat sich das Familienplanungsverhalten in der BRD seit 1985 verandert?]
  414. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
  415. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants.
  416. Incidence of breakthrough bleeding during oral contraceptive therapy.
  417. Age-specific differences in the relationship between oral contraceptive use and breast cancer.
  418. Alternative treatments in oral postcoital contraception: interim results.
  419. Association between contraceptive method accepted and perception of information received: a comparison of Norplant and IUD acceptors.
  420. The association of oral contraception with kidney cancer, colon cancer, gallbladder cancer (including extrahepatic bile duct cancer) and pituitary tumours.
  421. Barrier contraceptive methods and preeclampsia.
  422. Bone density in premenopausal women: effects of age, dietary intake, physical activity, smoking, and birth-control pills.
  423. Bone density in users of combined oral contraception. Preliminary reports of a pilot study.
  424. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
  425. Cardiovascular risk of oral contraceptives.
  426. Changes in haemostasis after stopping the combined contraceptive pill: implications for major surgery.
  427. The clinical and biochemical effects of two combination oral contraceptive agents.
  428. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users.
  429. Clinical experience with a new norgestimate-containing oral contraceptive.
  430. Clinical experience with triphasic oral contraceptive (Triquilar) in 527 women in China.
  431. Combined oral contraceptives containing chlormadinone acetate and breast cancer: results of a case-control study.
  432. A comparative study of 35 mcg and 50 mcg combined oral contraceptives: results from a multicenter clinical trial.
  433. A comparative study of a progestin-only oral contraceptive versus non-hormonal methods in lactating women in Buenos Aires, Argentina.
  434. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia.
  435. A comparison of Multiload with Copper-T IUDs in a family planning clinic in Lagos.
  436. Comparison of sequential cyproterone acetate / estrogen versus spironolactone / oral contraceptive in the treatment of hirsutism.
  437. Complexion changes in oral contraceptive users. Results from a phase IV multicenter trial evaluating the safety and efficacy of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms.
  438. Condom use and breakage among women in a municipal hospital family planning clinic.
  439. Condom use with regular and casual partners among women attending family planning clinics.
  440. Contraception and sexuality in an area-specific group of Swedish women 15-34 years of age.
  441. Contraception by cyclic treatment with Buserelin and progesterone. [Antikonzeption durch zyklische Behandlung mit Buserelin und Progesteron.]
  442. Contraception with cyclic administration of buserelin and progestogens: increase in serum concentrations of testosterone and free testosterone. [Kontrazeption durch zyklische Gabe von Buserelin und Gestagenen: Zunahme der Serumkonzentrationen von Testosteron und freiem Testosteron.]
  443. Contraceptive efficacy of lactational amenorrhea in urban Chilean women.
  444. Contraceptive female sterilization in Alabama: a replication of the WHO study.
  445. Contraceptive prevalence, reproductive health and our common future.
  446. Contraceptive use at first premarital intercourse: United States, 1965-1988.
  447. Coronary heart disease risk markers in users of low-dose oral contraceptives.
  448. Correlates of short interbirth intervals in Peninsular Malaysia: their pathways of influence through breastfeeding and contraceptive use.
  449. Costs and benefits of implementing family planning services at a private mining company in Peru.
  450. The CU SAFE 300 IUD, a new concept in intrauterine contraception: first-year results of a large study with follow-up of 1017 acceptors.
  451. Desogestrel and gestodene in oral contraceptives: 12 months assessment of carbohydrate and lipoprotein metabolism.
  452. A diaphragm tampon applied to an ovulation method in a birth control system.
  453. Do combined oral contraceptive users know how to take their pill correctly?
  454. Effect of family planning program components on contraceptive acceptance in four Indian states.
  455. Effect of long-acting progestagen-only injectable contraceptives on carbohydrate metabolism and its hormonal profile.
  456. Effect of long-term triphasic oral contraceptive use on glucose tolerance and insulin secretion.
  457. The effect of low-dose oral contraceptives on lipids and lipoproteins in two at-risk populations: young female smokers and older premenopausal women.
  458. The effect of tetracycline on levels of oral contraceptives.
  459. The effect on follicular growth and luteal function of "missing the pill". A comparison between a monophasic and a triphasic combined oral contraceptive.
  460. Effects of low and high dose oral contraceptives on blood coagulation and thrombogenesis induced by vascular subendothelium exposed to flowing human blood.
  461. The efficacy and acceptability of a low-dose levonorgestrel intravaginal ring for contraception in a UK cohort.
  462. Ethics and family planning.
  463. Evaluation and therapy of breakthrough bleeding in women using a triphasic oral contraceptive.
  464. Evaluation by women consulting in a family planning centre of their risk of HIV infection.
  465. An evaluation of the Bioself 110 electronic fertility indicator as a contraceptive aid.
  466. Failed contraception in Nigerian women: outcome of pregnancy and subsequent contraceptive choice.
  467. Family planning clinics: facing higher costs and sicker patients.
  468. Family planning knowledge, attitudes, and practices of men in Zimbabwe.
  469. Female university students in Sweden: sex, contraception and STDs.
  470. Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive.
  471. Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months.
  472. The Indonesian Family Planning Programme: a success story for women?
  473. Induced abortions, contraceptive practices, and tobacco smoking as risk factors for ectopic pregnancy in Athens, Greece.
  474. The influence of lactose consumption on the association of oral contraceptive use and ovarian cancer risk.
  475. Interchangeability of low-dose oral contraceptives. Are current bioequivalent testing measures adequate to ensure therapeutic equivalency?
  476. Interruption of pregnancy: motives, attitudes and contraceptive use. Interviews before abortion, at a family planning clinic, Rome.
  477. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study.
  478. Is persistent pelvic pain and pelvic joint instability associated with early menarche and with oral contraceptives?
  479. The lack of interaction between temafloxacin and combined oral contraceptive steroids.
  480. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
  481. A longitudinal study of contraception and pregnancy outcome in a representative sample of young Swedish women.
  482. Low estrogen oral contraceptives and the hypothalamo-pituitary axis.
  483. Menstrual bleeding patterns in untreated women and with long-acting methods of contraception.
  484. Morphometric studies of the endometrium, the fallopian tube and the corpus luteum during contraception with the 300 microgram norethisterone (NET) minipill.
  485. A multicenter clinical study on two types of levonorgestrel tablets administered for postcoital contraception.
  486. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations.
  487. A multicentred, two-year, phase III clinical trial of norethisterone enanthate 50 mg plus estradiol valerate 5 mg as a monthly injectable contraceptive.
  488. New female intravaginal barrier contraceptive device: preliminary clinical trial.
  489. Norplant implants: the mechanism of contraceptive action.
  490. Open prospective multicenter trial with a new monophasic contraceptive combination containing gestodene.
  491. An open prospective study on the effects on carbohydrate metabolism of an oral monophasic contraceptive containing gestodene (WL-70)
  492. Oral contraception: past, present, and future perspectives.
  493. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
  494. Oral contraceptive pill use after an initial visit to a family planning clinic.
  495. Oral contraceptive prescribing in the presence of risk factors.
  496. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation.
  497. Oral contraceptives and antithrombin III: variations by dosage and ABO blood group.
  498. Oral contraceptives and breast cancer: a French case-control study.
  499. Oral contraceptives and breast cancer: cause and effect?
  500. Oral contraceptives and cervical neoplasia.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.